Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | GRK2 | P25098 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18704704 | 0.83 | CA1 (0.67) | ALDH1A1PKMSMN1; SMN2CA1CA2 | |
| SCHEMBL12127405 | 0.83 | CNR1 (0.67) | ALDH1A1PKMSMN1; SMN2NPC1TSHR | |
| SCHEMBL1484465 | 0.81 | ALDH1A1 (0.63) | ALDH1A1PKMSMN1; SMN2NPC1TSHR | |
| SCHEMBL13461105 | 0.81 | MEN1 (0.64) | ALDH1A1PKMSMN1; SMN2NPC1TSHR | |
| SCHEMBL14281354 | 0.81 | TSHR (0.69) | ALDH1A1PKMSMN1; SMN2NPC1TSHR | |
| SCHEMBL7357569 | 0.81 | MEN1 (0.64) | ALDH1A1PKMSMN1; SMN2CA1CA2 | |
| SCHEMBL5331532 | 0.81 | ALDH1A1 (0.68) | ALDH1A1PKMSMN1; SMN2NPC1TSHR | |
| SCHEMBL4883987 | 0.81 | GAA (0.66) | ALDH1A1CA1CA2TSHRMEN1 | |
| SCHEMBL933945 | 0.80 | CNR1 (0.76) | ALDH1A1NPC1CNR1TRPV1CNR2 | |
| SCHEMBL4901981 | 0.80 | MEN1 (0.63) | ALDH1A1PKMSMN1; SMN2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080025940-A1 | Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof | L'OREAL (FR) | 2008-01-31 | — | — | US | claimed |
| EP-1853352-A2 | USE OF 3-SULFANYLPROPANAMIDE DERIVATIVES FOR STIMULATING HAIR AND EYELASH GROWTH AND/OR FOR STOPPING THE LOSS AND/OR LIMITING THE DEPIGMENTATION THEREOF | L'Oréal (FR) | 2007-11-14 | — | — | EP | claimed |
| WO-2006079568-A2 | USE OF 3-SULFANYLPROPANAMIDE DERIVATIVES FOR STIMULATING HAIR AND EYELASH GROWTH AND/OR FOR STOPPING THE LOSS AND/OR LIMITING THE DEPIGMENTATION THEREOF | L'OREAL (FR) | 2006-08-03 | — | — | WO | claimed |
| US-20220204497-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2022-06-30 | — | — | US | disclosed |
| US-20080025940-A1 | Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof | L'OREAL (FR) | 2008-01-31 | — | — | US | disclosed |
| US-20080025940-A1 | Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof | L'OREAL (FR) | 2008-01-31 | — | — | US | disclosed |
| US-20080025940-A1 | Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof | L'OREAL (FR) | 2008-01-31 | — | — | US | disclosed |
| EP-1853352-A2 | USE OF 3-SULFANYLPROPANAMIDE DERIVATIVES FOR STIMULATING HAIR AND EYELASH GROWTH AND/OR FOR STOPPING THE LOSS AND/OR LIMITING THE DEPIGMENTATION THEREOF | L'Oréal (FR) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006079568-A2 | USE OF 3-SULFANYLPROPANAMIDE DERIVATIVES FOR STIMULATING HAIR AND EYELASH GROWTH AND/OR FOR STOPPING THE LOSS AND/OR LIMITING THE DEPIGMENTATION THEREOF | L'OREAL (FR) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204497-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | TPX2, AIMP2, CDYL2 | ALDH1A1 2153/4885PKM 3901/4885SMN1; SMN2 1981/4885 |
| US-20080025940-A1 | Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof | KRT18, TYR, MC1R | ALDH1A1 1607/4885PKM 1605/4885SMN1; SMN2 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.